Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: J Immunol. 2011 Jun 22;187(3):1113–1119. doi: 10.4049/jimmunol.1100056

Figure 2. PDL1 blockade leads to accelerated cardiac allograft loss in B7.2-deficient but not in B7.1-deficient recipients.

Figure 2

bm12 cardiac grafts transplanted into B6 B7.1- or B7.2-deficient recipients had a median survival time of greater than 56 days. When treated with MIH6 anti-PDL1 mAb, B7.2-deficient recipients rejected all allografts within 10 days (B), while allografts survived long-term in B7.1- deficient recipients (A). N= 6 for each group.